[go: up one dir, main page]

ME02980B - Kondenzirani arilni i heteroarilni laktami - Google Patents

Kondenzirani arilni i heteroarilni laktami

Info

Publication number
ME02980B
ME02980B MEP-2018-8A MEP20188A ME02980B ME 02980 B ME02980 B ME 02980B ME P20188 A MEP20188 A ME P20188A ME 02980 B ME02980 B ME 02980B
Authority
ME
Montenegro
Prior art keywords
aryl
heteroaryl fused
fused lactams
lactams
heteroaryl
Prior art date
Application number
MEP-2018-8A
Other languages
German (de)
English (en)
French (fr)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ME02980B publication Critical patent/ME02980B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2018-8A 2012-12-21 2018-09-05 Kondenzirani arilni i heteroarilni laktami ME02980B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
PCT/IB2013/060682 WO2014097041A1 (en) 2012-12-21 2013-12-05 Aryl and heteroaryl fused lactams
EP13817739.9A EP2935238B1 (en) 2012-12-21 2013-12-05 Aryl and heteroaryl fused lactams

Publications (1)

Publication Number Publication Date
ME02980B true ME02980B (me) 2018-10-20

Family

ID=49917684

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2020-147A ME03793B (me) 2012-12-21 2013-12-05 Laktami kondezirani s arilom i heteroarilom
MEP-2018-8A ME02980B (me) 2012-12-21 2018-09-05 Kondenzirani arilni i heteroarilni laktami

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2020-147A ME03793B (me) 2012-12-21 2013-12-05 Laktami kondezirani s arilom i heteroarilom

Country Status (46)

Country Link
US (3) US9040515B2 (me)
EP (2) EP3339303B9 (me)
JP (1) JP5909308B2 (me)
KR (1) KR101712441B1 (me)
CN (1) CN104870435B (me)
AP (1) AP2015008574A0 (me)
AR (1) AR094174A1 (me)
AU (1) AU2013365908C1 (me)
BR (1) BR112015014678B1 (me)
CA (1) CA2893339C (me)
CL (1) CL2015001733A1 (me)
CR (2) CR20200273A (me)
CU (1) CU24414B1 (me)
CY (2) CY1119883T1 (me)
DK (2) DK3339303T3 (me)
DO (1) DOP2015000157A (me)
EA (1) EA028317B1 (me)
EC (1) ECSP15031579A (me)
ES (2) ES2808987T3 (me)
GE (1) GEP201706718B (me)
GT (1) GT201500190A (me)
HR (2) HRP20180060T1 (me)
HU (2) HUE038238T2 (me)
IL (1) IL239520B (me)
LT (2) LT2935238T (me)
MA (1) MA38175B1 (me)
MD (1) MD4664C9 (me)
ME (2) ME03793B (me)
MX (2) MX2015008058A (me)
MY (2) MY192259A (me)
NO (1) NO2961649T3 (me)
NZ (1) NZ708801A (me)
PE (1) PE20151090A1 (me)
PH (1) PH12015501367B1 (me)
PL (2) PL2935238T3 (me)
PT (2) PT2935238T (me)
RS (2) RS60582B9 (me)
SG (1) SG11201504076XA (me)
SI (2) SI2935238T1 (me)
TN (1) TN2015000281A1 (me)
TR (1) TR201802791T4 (me)
TW (1) TWI546293B (me)
UA (1) UA111305C2 (me)
UY (2) UY35225A (me)
WO (1) WO2014097041A1 (me)
ZA (1) ZA201504437B (me)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
DK3157915T3 (en) * 2014-06-17 2019-04-23 Pfizer Substituted dihydroisoquinolinone compounds
EP3212639A1 (en) * 2014-10-28 2017-09-06 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
EP3236962A2 (en) 2014-12-23 2017-11-01 University of Copenhagen Treatment of cancer by inhibiting ezh2 activity
BR112017020349B1 (pt) * 2015-03-27 2021-08-03 Syngenta Participations Ag Derivados heterobicíclicos microbicidas
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產(第二)有限公司 Zeste同源物2增強子之抑制劑
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
KR20180081587A (ko) 2015-11-19 2018-07-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤조푸란 유도체, 이의 제조 방법 및 의학에서의 이의 용도
PE20190106A1 (es) * 2016-05-05 2019-01-15 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homologo zeste 2
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018086589A1 (zh) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CA3058241A1 (en) 2017-05-18 2018-11-22 Jiangsu Hengrui Medicine Co., Ltd. Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
KR102612379B1 (ko) 2017-05-18 2023-12-12 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 벤조푸란 유도체 자유 염기의 결정 및 제조 방법
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
MX2020004731A (es) 2017-11-14 2020-10-28 Pfizer Terapias de combinacion de inhibidor ezh2.
EP4043466B1 (en) 2018-01-31 2024-08-21 Mirati Therapeutics, Inc. Prc2 inhibitors
JP2021527064A (ja) * 2018-06-07 2021-10-11 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Prc1阻害剤及びそれを用いた治療方法
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
EP3870173A4 (en) * 2018-10-24 2022-06-22 Vanderbilt University WDR5 INHIBITORS AND MODULATORS
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
CA3165787C (en) * 2020-08-13 2023-06-06 Seung Hyun Jung Novel dioxoloisoquinolinone derivatives and use thereof
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
CN116457348B (zh) * 2021-02-26 2024-11-26 南京迈晟科技有限责任公司 Ezh2抑制剂及其用途
CN120476107A (zh) 2022-12-15 2025-08-12 先正达农作物保护股份公司 可用作杀有害生物剂的新型的二环-甲酰胺化合物
CN118978498B (zh) * 2024-10-22 2025-04-01 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2619462A1 (en) 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
NZ603454A (en) 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
KR102511807B1 (ko) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 인간 ezh2의 억제제 및 이의 사용 방법
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) * 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2014049488A1 (en) 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
CN105452226B (zh) 2012-12-21 2017-09-12 Epizyme股份有限公司 四氢‑和二氢‑异喹啉prmt5抑制剂及其用途
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
EA026687B1 (ru) 2012-12-21 2017-05-31 Ф. Хоффманн-Ля Рош Аг Пептиды в качестве агонистов окситоцина
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
PT3067358T (pt) 2012-12-21 2019-11-18 Gilead Sciences Inc Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
SI2934568T1 (en) 2012-12-21 2018-03-30 Sanofi Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon
UY35240A (es) 2012-12-21 2014-07-31 Plexxikon Inc Compuestos y métodos para la modulación de quinasas y sus indicaciones
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
DK3157915T3 (en) 2014-06-17 2019-04-23 Pfizer Substituted dihydroisoquinolinone compounds

Also Published As

Publication number Publication date
CU24414B1 (es) 2019-05-03
US20150175572A1 (en) 2015-06-25
TW201446753A (zh) 2014-12-16
LT2935238T (lt) 2018-02-26
US20170233368A1 (en) 2017-08-17
MY192259A (en) 2022-08-12
ES2808987T9 (es) 2021-11-29
HK1208866A1 (en) 2016-03-18
CA2893339A1 (en) 2014-06-26
CL2015001733A1 (es) 2015-10-23
US20140179667A1 (en) 2014-06-26
MY176307A (en) 2020-07-28
MX2015008058A (es) 2015-10-30
MA38175A1 (fr) 2018-08-31
TWI546293B (zh) 2016-08-21
WO2014097041A1 (en) 2014-06-26
CR20150279A (es) 2015-09-03
EP3339303B1 (en) 2020-06-24
HRP20201194T1 (hr) 2020-11-13
KR20150100823A (ko) 2015-09-02
TR201802791T4 (tr) 2018-03-21
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
LT3339303T (lt) 2020-09-10
ES2808987T3 (es) 2021-03-02
MD4664B1 (ro) 2019-12-31
PE20151090A1 (es) 2015-08-07
ME03793B (me) 2021-04-20
CA2893339C (en) 2017-06-13
MD4664C9 (ro) 2020-07-31
ES2658974T3 (es) 2018-03-13
EP2935238B1 (en) 2017-12-27
RS60582B9 (sr) 2021-09-30
BR112015014678A2 (pt) 2017-07-11
AU2013365908B2 (en) 2017-07-20
HRP20201194T2 (hr) 2021-09-17
DOP2015000157A (es) 2015-11-30
RS56815B1 (sr) 2018-04-30
MD20150052A2 (ro) 2015-12-31
BR112015014678B1 (pt) 2021-12-07
CY1119883T1 (el) 2018-06-27
HUE050009T2 (hu) 2020-11-30
GEP201706718B (en) 2017-08-10
JP2016507497A (ja) 2016-03-10
EP3339303A1 (en) 2018-06-27
MX2020002924A (es) 2020-07-22
RS60582B1 (sr) 2020-08-31
JP5909308B2 (ja) 2016-04-26
SI2935238T1 (en) 2018-04-30
CU20150062A7 (es) 2015-11-27
EP3339303B9 (en) 2021-07-21
IL239520A0 (en) 2015-08-31
AP2015008574A0 (en) 2015-07-31
PT3339303T (pt) 2020-07-30
UA111305C2 (uk) 2016-04-11
EP2935238A1 (en) 2015-10-28
HRP20180060T1 (hr) 2018-02-23
ZA201504437B (en) 2016-07-27
NO2961649T3 (me) 2018-02-17
EA201590879A1 (ru) 2015-12-30
GT201500190A (es) 2016-01-21
DK3339303T3 (da) 2020-08-10
CR20200273A (es) 2020-09-23
UY35225A (es) 2014-07-31
EA028317B1 (ru) 2017-11-30
AU2013365908C1 (en) 2018-01-25
US9040515B2 (en) 2015-05-26
AU2013365908A1 (en) 2015-06-11
US10246433B2 (en) 2019-04-02
DK2935238T3 (en) 2018-01-22
AR094174A1 (es) 2015-07-15
UY38712A (es) 2020-06-30
PL3339303T3 (pl) 2021-01-25
TN2015000281A1 (fr) 2016-10-03
CY1123237T1 (el) 2021-10-29
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
ECSP15031579A (es) 2017-08-31
PH12015501367B1 (en) 2018-08-03
SI3339303T1 (sl) 2020-09-30
PH12015501367A1 (en) 2015-09-02
CN104870435A (zh) 2015-08-26
CN104870435B (zh) 2016-12-07
KR101712441B1 (ko) 2017-03-07
MA38175B1 (fr) 2018-11-30
IL239520B (en) 2018-05-31
HUE038238T2 (hu) 2018-10-29

Similar Documents

Publication Publication Date Title
HRP20201194T1 (hr) Laktami kondenzirani s arilom i heteroarilom
EP2935226A4 (en) HETEROARYL COMPOUNDS AND USES THEREOF
SG11201500927YA (en) Kimono
GB201200022D0 (en) Surveillance
ZA201503367B (en) Heteroaryl derivatives and uses thereof
SG11201403852UA (en) Fused pyrroledicarboxamides and their use as pharmaceuticals
ZA201504122B (en) Diazole lactams
AP3611A (en) Heterocyclic compounds and their uses
EP2894722A4 (en) THICK HEADED
EP2820499A4 (en) PROGRAMMABLE SENSORS
GB2505195B (en) Joint configuration
AU4710P (en) Fusion xTriticosecale
GB201215901D0 (en) Protein modification
GB201209803D0 (en) MK-V fusion system
GB201223020D0 (en) Tmf
GB201207694D0 (en) Mirror mate